Anixa Biosciences, Inc. (NASDAQ: ANIX) has received a new U.S. patent for its innovative breast cancer vaccine technology. The United States Patent and Trademark Office (USPTO) will officially issue Patent No. 12,472,205 on November 18, 2025, marking a major step forward for the company’s preventive cancer program.
The newly granted patent protects methods that trigger an immune response to the protein α-lactalbumin. This protein is normally present in breast tissue during lactation but is also found in certain types of breast cancer. By targeting α-lactalbumin, the vaccine aims to train the immune system to recognize and destroy emerging cancer cells before they form tumors.
The breast cancer vaccine was developed by researchers at the Cleveland Clinic, led by Dr. Vincent Tuohy and Dr. Justin Johnson. Anixa holds an exclusive worldwide license to this technology from the Cleveland Clinic. The company stated that the new patent extends its intellectual property protection for the vaccine into the mid-2040s, strengthening its long-term development and commercialization strategy.
According to Anixa’s CEO, the patent marks a key milestone in the company’s mission to create a first-of-its-kind preventive breast cancer vaccine. He emphasized that strong patent protection provides the foundation for advancing the vaccine through future clinical trials and regulatory stages.
Anixa’s breast cancer vaccine remains investigational and is currently in the clinical testing phase. Early-stage trials have focused on evaluating its safety and immune response in healthy volunteers and breast cancer survivors. The company plans to expand studies to assess the vaccine’s ability to prevent the onset of cancer in high-risk populations.
If successful, this vaccine could become a historic medical advancement, offering women a proactive way to prevent one of the world’s most common cancers.
